← Browse by Condition
Medical Condition
solid tumor adult
Total Trials
16
Recruiting Now
16
Trial Phases
Phase 2, Phase 3, Phase 1, Phase 2
NCT04353375 Phase 2, Phase 3
Recruiting
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
Enrollment
235 pts
Location
China
Sponsor
Hutchmed
NCT04196257 Phase 1
Recruiting
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Enrollment
50 pts
Location
United States
Sponsor
Bio-Path Holdings, Inc.
NCT05605119 Phase 1
Recruiting
First in Human, Dose Escalation, Dose Expansion Study of AUR105
Enrollment
40 pts
Location
India
Sponsor
Aurigene Discovery Technologie...
NCT04673942 Phase 2
Recruiting
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Enrollment
140 pts
Location
United States
Sponsor
EpicentRx, Inc.
NCT05481502
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Enrollment
160 pts
Location
France
Sponsor
Gustave Roussy, Cancer Campus,...
NCT06622486 Phase 1, Phase 2
Recruiting
First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors
Enrollment
50 pts
Location
France, Spain
Sponsor
Egle Therapeutics
NCT05359445 Phase 1
Recruiting
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Enrollment
95 pts
Location
Germany
Sponsor
Immatics Biotechnologies GmbH
NCT06436157
Recruiting
A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention
Enrollment
60 pts
Location
United States
Sponsor
University of California, Davi...
NCT05689853 Phase 1, Phase 2
Recruiting
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Enrollment
87 pts
Location
China
Sponsor
Akeso
NCT04928508 Phase 1
Recruiting
Advanced or Recurrent Solid Tumors Treated With SHetA2
Enrollment
50 pts
Location
United States
Sponsor
University of Oklahoma
NCT04282044 Phase 1
Recruiting
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Enrollment
60 pts
Location
United States
Sponsor
BioEclipse Therapeutics
NCT03686124 Phase 1, Phase 2
Recruiting
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Enrollment
375 pts
Location
United States, Germa...
Sponsor
Immatics US, Inc.
NCT05071846 Phase 1
Recruiting
MVX-ONCO-2 in Advanced Solid Tumors
Enrollment
6 pts
Location
Switzerland
Sponsor
University Hospital, Geneva
NCT06895733 Phase 1, Phase 2
Recruiting
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
Enrollment
65 pts
Location
China
Sponsor
Tianjin Medical University Sec...
NCT06478108 Phase 2, Phase 3
Recruiting
Interventional Software for Multi-immunotherapy of Solid Tumors
Enrollment
60 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
NCT03004755
Recruiting
The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study
Enrollment
500 pts
Location
United Kingdom
Sponsor
University College, London